N-Acetyl Semax10mg
N-Acetyl Semax Canada — 10 mg Lyophilized Vials
ACTH(4-10)-Analogue Nootropic Peptide
Also known as N-Acetyl Semax (Semax analogue)
N-Acetyl Semax is an N-acetylated form of Semax, a synthetic analogue of an ACTH(4-10) fragment, studied in research for nootropic and neuroprotective signaling.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off vials.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
N-Acetyl Semax is an N-acetylated form of Semax, a synthetic analogue of an ACTH(4-10) fragment, studied in research for nootropic and neuroprotective signaling.
Experimental models examine its effects on neurotrophic and monoaminergic pathways under controlled laboratory conditions.
Third-party tested for purity, ID, quantity.
Semax is a synthetic ACTH(4-10) analogue characterized in research for nootropic and neuroprotective activity, including activation of dopaminergic and serotonergic systems and modulation of BDNF-related signaling. The N-acetylated form is studied for peptide stability within the same framework.
Studies span nootropic, neuroprotection, and neuroinflammation research under structured conditions.
Semax was developed from research into short ACTH-fragment analogues lacking corticotropic activity but retaining neurotropic effects.
Research has characterized its cognitive and neuroprotective endpoints; the N-acetyl form shares this lineage.
Research into Semax-class peptides focuses on nootropic and neuroprotective models. Frameworks evaluate monoaminergic activation, neurotrophic signaling, and neuroinflammation endpoints under controlled preclinical conditions.
2 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Eremin 2005, Medvedeva 2014, Safarova 2002. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Eremin 2005, Safarova 2002. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on monoaminergic or neurotrophic. This heading marks where N-Acetyl Semax is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on neuroinflammation. This heading marks where N-Acetyl Semax is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 3 primary papers published between 2002 and 2014 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for N-Acetyl Semax, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
N-Acetyl Semax is also referred to as NA-semax, acetyl semax, and technically as N-Acetyl Semax (Semax analogue).
N-Acetyl Semax is commonly described online in connection with sharper focus, better memory and improved mood. In the research literature the same compound is filed under ACTH(4-10)-analogue peptide models, nootropic and cognitive research and monoaminergic and neurotrophic studies.
The 3 papers cited on this page, published between 2002 and 2014 (2 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for N-Acetyl Semax is per lot, not per product. The current 10mg lot NASA-CA-26F-10 returned 99.303% purity, 11.58 mg measured, 115.8% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is N-Acetyl Semax; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for N-Acetyl Semax, this lot measured 115.8% of its labelled 10 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for N-Acetyl Semax. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy N-Acetyl Semax in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
N-Acetyl Semax is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 7 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of n acetyl semax. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents
PubMedThe peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis
PubMedTrophic effects of nootropic peptide preparations cerebrolysin and semax on cultured rat pheochromocytoma
PubMedRelated
Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$59.95CAD
Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$34.95CAD
Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$54.95CAD
Out of stockPeptides
Long-Acting Amylin Analogue · 5 & 10 mg Cagrilintide is a synthetic peptide developed for controlled laboratory research involving amylin receptor signaling systems. It is structurally designed to interact with amylin-associated pathways within experimental environments.
CAG-CA-26A-0199.446%
5.62 mg / 5 mg
$69.95CAD
